Poly Medicure Q3 Results Review - 20% Plus Growth Guidance For FY25: Systematix

Systematix Report

Poly Medicure Ltd.'s Q3 FY24 Earnings were in line with consensus but 5% below our expectations. Revenue growth was 19.2% on a YoY basis, which was lower than their historical trend of 20% plus. For FY25, company expects the growth to remain 20% plus and also believes there is a reasonable chance for the business growth to outpace current expectations.

Three out of the four new manufacturing facilities have been operationalized and should help them service the growing market demand for their products. In the domestic market, the field force has been expanded to service their newly set up critical care and cardiology divisions which will focus on high value products.

In the renal segment growth was lackluster in FY24 and expect the same to accelerate meaningfully in FY25. With regard to dialysis machines, the company has increased the proportion of components domestically sourced to more than 50% and this should put them in a better position while bidding for Government tenders.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.